The development of allergic asthma is thought to involve environmental and inherited genetic components and has pathophysiological features reflecting in part the activity of T cell cytokines. Interleukin-13, a product primarily of activated lymphocytes, is considered to be a critical effector molecule in allergic airway response and has been found to be overexpressed in the airways of patients with asthma. The IL-13 gene is located on chromosome 5q31, one of the major loci to be linked to asthma susceptibility, and amongst a cluster of genes which dominate the immunopathology of allergic disease. Recently, an IL-13 promoter polymorphism was found to be associated with allergic asthma. In the present study we report the identification of four novel biallelic polymorphisms in the IL-13 gene, two intronic and two exonic, one of which results in a basic to hydrophilic amino acid change. We characterised the frequencies of these four biallelic polymorphisms and the frequencies of the haplotypes, resulting from the combination of these four biallelic polymorphisms, in a population of 196 UK Caucasoid healthy individuals. Genes and Immunity (2000) 1, 341-345.
Numerous studies have demonstrated that CD4
+ T lymphocytes regulate the inflammatory response observed in asthma via the release of specific cytokines, in particular the T helper cell type 2 (T H 2) cytokines, which include interleukin-4 (IL-4) and IL-5.
1-4 IL-13 is biologically closely related to IL-4 and shares signal transduction elements as well as receptor components with IL-4. [5] [6] [7] [8] It is produced at high levels by CD4
+ T H 2 cells after activation 9 but has also been found to be produced by other T cell subsets including T H 0 9 and CD8 +9 T cells. One of the most important similarities with IL-4 is the ability to induce IgE production 5, 6, [10] [11] [12] but unlike IL-4, IL-13 is ineffective in directing T H 2-cell differentiation. 7 Evidence suggesting a critical role for IL-13 in asthma comes from well-characterised experimental murine models of allergic asthma 13, 14 and the selective expression of IL-13 in the lungs of transgenic mice. 15 In these models, elements of the effector phase of asthma (such as airway hyperresponsiveness, mucus overproduction, bronchoalveolar lavage fluid eosinophilia, subepithelial fibrosis, as well as increased total serum IgE and increased production of the eosinophil chemoattractant, eotaxin) were all associated with IL-13 overproduction. In humans, increased expression of IL-13 has been observed in bronchial biopsies from atopic asthmatics 16 and peripheral blood mononuclear cells from atopic patients.
The human IL-13 gene is located on chromosome 5q31, approximately 12 kb upstream from the IL-4 gene and within the region of chromosome 5 that has been linked to asthma susceptibility by large-scale familial linkage studies. [18] [19] [20] [21] Recently, the screening of several transgenic animals carrying large inserts of human chromosome 5q31 revealed that altered IgE response to antigen provocation was linked to a 180-kb region of chromosome 5q31 that contained the IL-4 and IL-13 genes and that moderate changes in IL-4 and IL-13 expression affected asthmaassociated phenotypes. 22 The observation of inter-individual variability in the spontaneous IL-13 expression by peripheral blood mononuclear cells from both normal and asthmatic individuals suggest that potential polymorphisms may exist within the IL-13 gene and these may confer susceptibility to allergy and asthma. 17 Recently, van der Pouw Kraan et al 23 reported the existence of a C to T single nucleotide polymorphism (SNP) at nucleotide position (nt) −1055 in the promoter region of the IL-13 gene which was shown to affect IL-13 production and to be associated with increased risk of allergic asthma. 23 However, Anderson et al 24 have reported the absence of polymorphic variants for the region of the IL-13 gene spanning −1039nt to +80nt.
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By comparing the region downstream of nucleotide +80 in four IL-13 gene sequences deposited in the GenBank™ database, we identified four potential single nucleotide variations. Numbered from the first nucleotide of the start codon, the four potential SNPs were: a G/C at +543nt, a C/T at +1922nt, a G/A at +2043nt and a C/A at +2579nt. In the published sequence of human IL-13 gene with accession number L13029, 25 these four potential SNPs correspond to nucleotide positions 1314, Consensus to +543nt 5′-gCC ATT gCA gAg Cgg AgC 004 2693, 2814 and 3350 respectively. The variations at positions +543nt and +1922nt are located in introns 1 and 3 respectively; the variations at positions +2043nt and +2579nt are located in the translated and 3′-untranslated regions of exon 4 respectively. The G to A substitution at position +2043nt changes the codon sequence CGG that encodes for the basic amino acid arginine (Arg) at amino acid position 130 of the unprocessed IL-13 protein precursor, to CAG that encodes the hydrophilic amino acid glutamine (Gln).
To confirm the existence of these potential polymorphisms we used sequence-specific primer-PCR (SSP-PCR) Control PCR product using primer pair 63/64 at a final concentration of 0.2 m. All PCR reactions were performed as previously described and products were visualized on a 2% agarose gel. 25 Final concentration for each primer refers to the concentration in the 13 L reaction volume. methodology that we have used previously to confirm the existence of SNPs in the tumor necrosis factor receptor 2 gene. 26 We designed sequence-specific primers with 3′-end mismatches identifying each of the variants at the four polymorphic sites (Table 1) , we used the specific primers to identify the individual variants in each polymorphic position by PCR amplification. By using forward and reverse allele-specific primer combinations we could identify the cis/trans orientation of the alleles (Table 2 ). An appropriate set of control primers amplifying a 256-bp fragment of the human adenomatous polyposis coli gene (primers 210/211) or a 796-bp fragment of the DRB gene (primers 63/64) (Tables 1 and 2 ), added to all reactions confirmed PCR amplification where the variant was absent.
Using the DNA from an initial population of 50 UK controls we were able to confirm the presence of single nucleotide variations at the four sites identified by sequence comparisons with the frequency of the rarest allele +543nt-C being observed in four of the 50 individuals. Subsequently, we examined the frequency of all four SNPs in the total 196 UK Caucasoid controls, all of which were cadaveric renal allograft donors collected from around the UK by the Oxford Transplant Centre, Churchill Hospital, Oxford, and whose representative nature for UK Caucasians has previously been demonstrated in HLA genotyping studies. 27 The genotype and allelic frequencies of the four IL-13 polymorphisms are shown in Table 3 .
Examination of the association between the allelic variants using 2 test for independence with Yates' correction and corrected for multiple comparisons (according to the formula pc = 1 − (1−p) n , where pc is the corrected value, p the uncorrected value, and n the number of allelic comparisons) showed that the alleles G at +543nt, C at +1922nt, G at +2043nt, and C at +2579nt were strongly linked with each other (pc Ͻ 0.0001 for all combinations). Similarly, a strong association was observed between C at +543nt, T at +1922nt, A at +2043nt and A at +2579nt (pc Ͻ 0.001 for all combinations). However, these allelic associations were not absolute in all individuals. Using our methodology, we were able to determine the cis/trans relationship of the allelic variants thus defining individual haplotypes. The combination of the four biallelic polymorphisms can potentially give rise to 16 haplotypes. In the present study we observed eight haplotypes in our UK populations which we designated A to H (Table 4) examples of which are shown in Figure 1 . The genotype frequencies of these haplotypes, the frequencies of these haplotypes in the control population (carriage frequency) and the haplotype frequencies in the chromosomal pool (allele frequency) of the 196 UK control subjects are shown in Table 5 . Although it is not yet known whether these newly described polymorphisms are of functional significance, Figure 1 Shown is an example of two DNA samples that underwent PCR amplification using the allele specific primer mixtures 1 to 18 as stated in Table 5 . The PCR products were separated in a 2% agarose gel; M = 100 bp DNA ladder (Life Technologies Ltd, Paisley, UK). DNA sample A produced positive reactions with primer mixtures 1, 4, 8, 12, and 15 indicating that this individual is homozygous for alleles G, C, G and C at positions +543nt, +1922nt, +2043nt and +2579nt respectively. DNA sample B produced positive reactions with primer mixtures 1, 3, 4, 7, 8, 12, 13, 15 and 16 indicating that this individual is homozygous for the G allele at position +543 but heterozygous (C/T), (G/A), (C/A) at positions +1922nt, +2043nt and +2579nt respectively. From the primer combinations, and the haplotype nomenclature of Table 4 , it can be deduced that individual A has the AA genotype whereas individual B the AB genotype. 
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a case for a functional role can be made for at least three of them. First, McKenzie et al 6, 25 have identified the existence of two forms of IL-13 which differ by the presence or absence of amino acid residue Gln 98. The variants are thought to be the result of alternative splicing of the Gln 98 codon at the 5′ end of exon 4 but it is not yet known what regulates the transcription of either alternative spliced form of IL-13 mRNA. The dinucleotide (C/T) polymorphism at +1922nt is located only 24nt upstream of the Gln 98 codon. The close proximity of this polymorphism to the alternative spliced codon, could be relevant in the regulation of expression of the alternative spliced forms of the IL-13 gene.
Second, in order to examine the potential significance of a Gln or Arg at amino acid residue 130, which is regulated by the polymorphism at +2043nt, we used the Automated Protein Modeling Server SWISS-MODEL [28] [29] [30] [31] to predict the effect of either amino acid on the three-dimensional structure of the mature IL-13 protein. We examined both possibilities also taking into account the existence of the two alternative forms of IL-13 that result from the presence or absence of Gln at amino acid position 98. The model predicted an apparent conformational change in the tertiary structure when Arg at amino acid residue 130 was substituted for Gln; this appeared to be even greater in the absence of Gln at amino acid position 98. Whether this predicted conformational change affects the function of IL-13 needs to be established experimentally. Finally, a potential functional role for the (C/A) polymorphism at +2579nt can be argued because of its location in the 3′ untranslated region which has been shown to be involved in the regulation of mRNA stability in many cytokines.
It will be important in future studies to assess whether these four novel IL-13 polymorphisms are in linkage disequilibrium with the recently identified IL-13 promoter polymorphism 23 or with other polymorphisms in the 5q31 region such as those in the IL-4 gene. It is also equally vital to establish whether these new polymorphisms are functional and if so independently of the promoter polymorphism and whether these newly described IL-13 polymorphisms confer susceptibility to and/or severity of atopy and asthma.
